[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trialXilin Wu, Morris J. Brown, Wilson Tan et al.|Nature Medicine|2023Cited by 137
Molecular Imaging Versus Adrenal Vein Sampling for the Detection of Surgically Curable Primary AldosteronismEmily Goodchild, Morris J. Brown, Xilin Wu et al.|Annals of Internal Medicine|2025Cited by 26
Endoscopic, ultrasound-guided, radiofrequency ablation of aldosterone-producing adenomas (FABULAS): a UK, multicentre, prospective, proof-of-concept trialGiulia Argentesi, Xi‐Lin Wu, Alexander Ney et al.|The Lancet|2025Cited by 25
A Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[<sup>18</sup>F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary AldosteronismDaniel Gillett, Mark Gurnell, Russell Senanayake et al.|Journal of Nuclear Medicine|2025Cited by 11
FRI156 Novel Radiolabeled Ligand, Para-chloro-2-[18F]fluoroethyletomidate (CETO) Is Equivalent To [11C]metomidate-PET (MTO) For The Lateralisation Of Primary Aldosteronism (PA)Emily Goodchild, Morris J. Brown, Russell Senanayake et al.|Journal of the Endocrine Society|2023Cited by 0